Fox Run Management L.L.C. Has $1.01 Million Holdings in RxSight, Inc. (NASDAQ:RXST)

Fox Run Management L.L.C. lifted its position in shares of RxSight, Inc. (NASDAQ:RXST) by 47.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 29,458 shares of the company’s stock after buying an additional 9,443 shares during the quarter. Fox Run Management L.L.C.’s holdings in RxSight were worth $1,013,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the company. RA Capital Management L.P. increased its position in shares of RxSight by 6.0% during the third quarter. RA Capital Management L.P. now owns 3,916,825 shares of the company’s stock worth $193,609,000 after buying an additional 222,000 shares during the period. State Street Corp increased its position in shares of RxSight by 8.3% during the third quarter. State Street Corp now owns 817,671 shares of the company’s stock worth $40,417,000 after buying an additional 62,349 shares during the period. Geode Capital Management LLC increased its position in shares of RxSight by 17.7% during the third quarter. Geode Capital Management LLC now owns 817,117 shares of the company’s stock worth $40,398,000 after buying an additional 122,775 shares during the period. Point72 Asset Management L.P. increased its position in shares of RxSight by 610.2% during the third quarter. Point72 Asset Management L.P. now owns 446,976 shares of the company’s stock worth $22,094,000 after buying an additional 384,041 shares during the period. Finally, Thrivent Financial for Lutherans grew its holdings in RxSight by 53.6% in the fourth quarter. Thrivent Financial for Lutherans now owns 352,626 shares of the company’s stock worth $12,124,000 after purchasing an additional 122,989 shares during the period. 78.78% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. Stifel Nicolaus reduced their price target on shares of RxSight from $33.00 to $28.00 and set a “hold” rating for the company in a report on Wednesday. JPMorgan Chase & Co. reduced their price target on shares of RxSight from $62.00 to $40.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. Bank of America reduced their price target on shares of RxSight from $60.00 to $36.00 and set a “buy” rating for the company in a report on Friday. Needham & Company LLC restated a “buy” rating and issued a $43.00 price target on shares of RxSight in a report on Wednesday, February 26th. Finally, Wells Fargo & Company reduced their price target on shares of RxSight from $40.00 to $35.00 and set an “equal weight” rating for the company in a report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $49.33.

RxSight Trading Down 0.2 %

RxSight stock opened at $24.84 on Friday. RxSight, Inc. has a 1-year low of $24.09 and a 1-year high of $66.54. The firm has a market capitalization of $1.01 billion, a price-to-earnings ratio of -29.93 and a beta of 1.22. The firm’s fifty day moving average price is $29.63 and its two-hundred day moving average price is $40.05.

RxSight (NASDAQ:RXST) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.25). RxSight had a negative net margin of 23.92% and a negative return on equity of 14.00%. The business had revenue of $40.21 million during the quarter, compared to the consensus estimate of $40.23 million. On average, research analysts forecast that RxSight, Inc. will post -0.7 EPS for the current year.

Insider Activity at RxSight

In related news, Director Tamara Fountain sold 7,000 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $25.71, for a total transaction of $179,970.00. Following the transaction, the director now directly owns 24,793 shares of the company’s stock, valued at $637,428.03. This trade represents a 22.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Shweta Maniar sold 3,519 shares of the firm’s stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $30.87, for a total transaction of $108,631.53. Following the transaction, the director now directly owns 7,383 shares in the company, valued at $227,913.21. The trade was a 32.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.36% of the stock is owned by insiders.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.